EUCTR2010-023589-39-AT进行中（未招募）不适用
A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent Crohn's Disease where oral ferrous preparations have failed or cannot be used (AEGIS 2) - ST10-021 for IDA in quiescent CD
Iron Therapeutics (Switzerland) AG0 个研究点目标入组 60 人开始时间: 2011年5月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.1.Subject must be competent to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent form and must sign and date the informed consent prior to any study mandated procedure
- •2.Subject must be willing and able to comply with study requirements
- •3.Subject must be at least 18 years of age
- •4.Subject must have a current diagnosis of quiescent CD and IDA, as defined by the following criteria:
- •a.Subject must have quiescent CD defined by a Crohn’s Disease Activity Index (CDAI) score of < 220 at the Randomisation Visit
- •b.Subject must have anaemia defined by Hb ? 9.5 g/dl and <12.0 g/dl (5.9 - 7.5 mmol/l) for females and ?9.5 g/dl and <13.0 g/dl (5.9 - 8.1 mmol/l) for males as measured at the Screening Visit
- •c. Subject must have iron deficiency defined by ferritin < 30 µg/l as measured at the Screening Visit
- •5.Subject must have failed OFP in the past. Failure defined by:
- •a.Adverse drug effects that led to withdrawal from OFP (at least one of the following: nausea, diarrhoea, constipation, abdominal pain, flatulence) and/or
- •b.Deterioration of the primary disease caused by OFP and/or
- •c.Lack of efficacy and/or
- •d.Other signs of failure to OFP or reasons why OFP cannot be used as documented by the Investigator
- •6.Subject receiving protocol-allowed immunosuppressants at screening must have been on stable dose for at least 4 weeks prior to randomisation. Allowed immunosuppressants include azathioprine, 6-mercaptopurine, TNF-alpha antagonists and corticosteroid doses less than or equal to the equivalent of 25mg/day prednisolone.
- •7.Female subject of childbearing potential (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of contraception until study completion and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomised partner. Oral contraceptive medications are allowed in this study. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal (defined as no menstrual period within 1 year of screening) are also allowed to participate
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 51
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 9
排除标准
- •1.Subject with anaemia due to any cause other than iron deficiency, including, but not limited to,
- •a.Untreated or untreatable severe malabsorption syndrome
- •b.Immunosuppressant use
- •2.Subject who has received within 12 weeks prior to randomisation
- •a.Intramuscular or intravenous (IV) injection or administration of depot iron preparation
- •b.Blood transfusion
- •c.Erythropoietin
- •3.Subject who has received within 4 weeks prior to randomisation
- •a.Oral iron supplementation
- •b.Immunosuppressant with known effect of anaemia induction, including, but not limited to methotrexate, cyclosporin A or tacrolimus
- •4.Subject who has received Vitamin B12 injections/infusions within 4 weeks prior to randomisation.
- •5.Subject who has received a Folic Acid injection/infusion within 4 weeks prior to randomisation.
- •6.Subject with or Vitamin B-12 concentration below the lower limit of normal (LLN) as measured at the Screening Visit.
- •7.Subject with or folic acid deficiency as measured at the Screening Visit.
- •8.Subject with known hypersensitivity or allergy to ST10-021 or components of the study medication
- •9.Subject with contraindication for treatment with iron preparations, e.g. haemochromatosis, chronic haemolytic disease, sideroblastic anaemia, thalassaemia, or lead intoxication induced anaemia
- •10.Subject with creatinine > 2.0 mg/dl (176 µmol/l) as measured at the Screening Visit
- •11.Subject with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels = 5 times the upper limit of normal as measured at the Screening Visit
- •12.Subject with cardiovascular, liver, renal, haematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject
- •13.Subject with history of malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma
- •14.Subject with significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results (e.g., Alzheimer’s disease, schizophrenia or other psychosis, alcohol or drug abuse)
- •15. Participation in another interventional clinical study within 4 weeks prior to randomisation or during the study
- •16.Subject who is an inmate of a psychiatric ward, prison, or other state institution
- •17.Subject who is an Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
- •18.Subject with scheduled or expected hospitalisation and/or surgery during the course of the study
- •19.Female subject who is pregnant or lactating
研究者
相似试验
进行中（未招募）
1 期
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)Patients with severe COPDEUCTR2012-005586-13-ESAB SCIENCE30
进行中（未招募）
不适用
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2010-021495-29-FRAB Science
进行中（未招募）
1 期
Evaluation of masitinib in acute ischemic strokepatients suffering from Acute Ischemic StrokeMedDRA version: 18.1Level: LLTClassification code 10023027Term: Ischaemic stroke NOSSystem Organ Class: 100000004852EUCTR2010-020603-79-SKAB Science48
进行中（未招募）
不适用
Clinical study for the assessment of the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe COPD with elevated eosinophils level.EUCTR2012-005586-13-GRAB Science45
进行中（未招募）
不适用
A study of a new iron medication for people with Crohn's Disease that is in remission and anaemia (low number of healthy red blood cells), who cannot use other oral iron medications either because they do not work, or because they cause side effects. (AEGIS 2)Iron deficiency anaemia in quiescent Crohn's DiseaseMedDRA version: 14.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-023589-39-HUIron Therapeutics (Switzerland) AG60